Web-based tool for end-of-life planning in advanced cancer patients
Testing the Utility of a Novel Website to Help Cancer Patients Plan for Their Future - Phase 2
This study tests a new online tool designed to help people with advanced cancer plan for end-of-life care and see if it makes them feel less stressed and more prepared compared to standard care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fred Hutchinson Cancer Center Academic / other |
| Locations | 1 site (Seattle, Washington) |
| Trial ID | NCT05564468 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates a web-based tool developed in collaboration with Peacefully, Inc. to enhance end-of-life planning for patients with advanced cancers. Participants are randomized into two groups: one receiving the web-based tool and the other receiving standard care. The study assesses patient engagement in end-of-life planning at baseline and four weeks after randomization, with follow-ups at 4, 12, and 24 weeks. The goal is to reduce distress and improve preparation for end-of-life among patients facing serious illness.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with poor prognosis advanced cancer who have access to a computer or mobile device.
Not a fit: Patients who are not fluent in English or are severely cognitively impaired may not benefit from this study.
Why it matters
Potential benefit: If successful, this tool could significantly improve the quality of end-of-life planning and reduce anxiety for patients with advanced cancer.
How similar studies have performed: Other studies have shown promise in using digital tools for health planning, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of poor prognosis advanced cancer defined as locally advanced or metastatic cancer and/or disease progression following at least first line systemic therapy * Access to a computer or mobile device * The ability to provide informed consent Exclusion Criteria: * Not fluent in English * Severely cognitively impaired (as measured by Short Portable Mental Status Questionnaire scores of \< 6) * Too ill or weak to complete the interviews (as judged by the interviewer)
Where this trial is running
Seattle, Washington
- Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States (Recruiting)
Study contacts
- Principal investigator: Megan J. Shen — Fred Hutch/University of Washington Cancer Consortium
- Study coordinator: Megan J. Shen
- Email: mshen2@fredhutch.org
- Phone: 206-667-4172
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.